Day: November 4, 2021

FREMONT, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) — ACM Research, Inc. (“ACM”) (NASDAQ: ACMR), a leading supplier of wafer cleaning technologies for advanced semiconductor devices, today advised that the Shanghai Stock Exchange has announced the pricing of the initial public offering (“IPO”) of shares of ACM’s operating subsidiary ACM Research (Shanghai), Inc. (“ACM Shanghai”) on the Shanghai Stock Exchange’s Sci-Tech innovAtion boaRd (the “STAR Market”). In the IPO, ACM Shanghai proposes to issue 43,355,753 shares, which will represent 10% of the total 433,557,100 shares to be outstanding after the IPO. Of the shares issued in the IPO, 7,699,357 shares will be issued via direct placement to private equity investors. The proposed offering price of shares in the IPO is RMB 85.00 per share, which, if completed, would result in...

Third Quarter Net Revenue of $2.6 MillionUp 24% Year-Over-Year and 16% Quarter-over-Quarter  SOUTH ORANGE, NJ, Nov. 04, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Nephros, Inc.(Nasdaq: NEPH), a leading water technology company providing filtration and pathogen detection solutions to the medical and commercial markets, today announced results for the three months ended September 30, 2021. Financial Highlights Water Filtration Business Segment Highlights*Net revenue of $2.6 million, an increase of 22% Net loss of $0.8 million, an increase of 92% Adjusted EBITDA of ($0.3 million) an improvement of 6%Consolidated Highlights*Net revenue of $2.6 million, an increase of 24% Net loss of $1.2 million, an increase of 15% Adjusted EBITDA of ($0.7 million), an improvement of 22%*Stated performance is relative to same period...

Submitted New Drug Application (NDA) for roflumilast cream for the treatment of plaque psoriasis across the full spectrum of disease Initiated single pivotal Phase 3 trial of roflumilast foam in scalp and body psoriasis Enrolling pivotal Phase 3 trials of roflumilast cream in atopic dermatitis and roflumilast foam in seborrheic dermatitis Expanded patent portfolio with issuance of first pharmacokinetics patent covering both the cream and foam formulations of topical roflumilast Strong financial position with approximately $370 million in cash, cash equivalents, and marketable securities, providing cash runway well into 2023WESTLAKE VILLAGE, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology...

Achieves profitability on revenues of $5.5 million, up sharply from $1.6 million a year ago Affirms expectations for continued growth in 4Q and full-year profitability Conference call begins at 4:30 p.m. Eastern time today BOCA RATON, Fla., Nov. 04, 2021 (GLOBE NEWSWIRE) — Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces financial results for the three and nine months ended September 30, 2021. Highlights from the third quarter of 2021 and recent weeks include the following (all comparisons are with the third quarter of 2020, unless otherwise indicated):Revenues were $5.5 million, up 244% Net income was $0.2 million, or $0.01 per diluted share, compared with...

New Clinical Data from the ALPHA, ALPHA2 and UNIVERSAL AlloCAR T™ Trials to be Presented at the 63rd Annual Meeting of the American Society of HematologyALPHA2 Study Abstract Selected for Oral Presentation Highlights the Benefits of Consolidation Dosing with ALLO-501A in Patients with Relapsed/Refractory Large B Cell Lymphoma ALPHA Study Abstract Selected for Poster Presentation Continues to Show Durability of Responses to ALLO-501 in Patients with Non-Hodgkin Lymphoma UNIVERSAL Study Abstract Selected for Oral Presentation Reports Meaningful Activity of a Single Dose of ALLO-715 in Patients with Relapsed/Refractory Multiple MyelomaDiscussions Ongoing as Company Seeks to Resolve FDA Clinical Hold Ended Third Quarter with $862 Million in Cash, Cash Equivalents and Investments Conference Call and Webcast Scheduled for 2:00 PM PT/5:00...

Customer Additions of 30,698 in Q3, Bringing Total Customers to 630,441, 20% year-over-year growth in Customers pro-forma for Vivint Solar Net Subscriber Value of $7,605 in Q3, an increase of $2,031 from Q2 Annual Recurring Revenue of $787 Million with Average Contract Life Remaining of 17.3 years Net Earning Assets of $4.5 billion, including $941 million in Total Cash Networked Solar Energy Capacity of 4.5 Gigawatts SAN FRANCISCO, Nov. 04, 2021 (GLOBE NEWSWIRE) — Sunrun (Nasdaq: RUN), the nation’s leading provider of residential solar, storage and energy services, today announced financial results for the third quarter ended September 30, 2021. “Sunrun is empowering customers by offering clean, affordable and resilient energy options, while also addressing the urgent need to decarbonize our economy to combat climate change,” said...

MONTREAL, Nov. 04, 2021 (GLOBE NEWSWIRE) — Senvest Capital Inc. today reported net loss attributable to common shareholders of ($51.2) million or ($19.27) per share for the three months ended September 30, 2021. This compares to a net income attributable to common shareholders of $28.9 million or $10.83 per share for the same period in 2020. For the nine months ended September 30, 2021, the net income attributable to common shareholders was $674.0 million or 265.29 per share compared to a net loss attributable to common shareholders of ($151.9) million or ($57.69) per share the prior year. Financial statements are available online at Sedar www.sedar.com    CONSOLIDATED STATEMENT OF INCOME    (unaudited)    (in millions of dollars, except per share amounts)         For the three months ended   For the nine months...

– Announced strategic long-term exosome manufacturing collaboration with Lonza – – Initial data readout from exoSTING™ clinical trial expected in Q4 2021; initial data from exoIL-12™ trial in CTCL patients now anticipated in H1 2022 – – Investigational New Drug (IND) application filing for exoASO™-STAT6 expected in Q4 2021 – – Preclinical data showing new potential therapeutic applications for three engineered exosome candidates to be presented during SITC 2021 next week – CAMBRIDGE, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) — Codiak BioSciences, Inc. (NASDAQ: CDAK), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class of medicines, today reported third quarter 2021 financial results and recent operational progress. “We made steady progress in the third quarter toward our...

Third quarter 2021 revenue grew 17% sequentially and 38% over third quarter 2020 Company to host a conference call and webcast today, November 4, 2021 at 4:30 pm ET ROCKAWAY, N.J., Nov. 04, 2021 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced third quarter 2021 financial results and provided an operational update. Third Quarter 2021 and Recent HighlightsRevenue of $1.5 million, representing an increase of 17% sequentially and 38% over third quarter 2020 Gross margin expanded to 76% Net cash used to fund operations was $3.4 million, leaving approximately $39.0 million of cash, cash equivalents, and marketable securities at September 30, 2021 Dan Goldberger, Chief Executive Officer of electroCore, commented, “We are pleased that our third quarter results...